Literature DB >> 2191634

Combination of converting enzyme inhibitor with diuretic for the treatment of hypertension.

R R Townsend1, O B Holland.   

Abstract

In recent years there has been increased discussion about goals of antihypertensive therapy other than blood pressure reduction. The development of angiotensin-converting enzyme inhibitors has provided a class of drugs with a very low side-effect profile. However, single-drug therapy is effective in only about half of hypertensive patients. In the past, diuretics have traditionally been used as the initial or second antihypertensive. Increasingly, diuretic therapy is being avoided, and other antihypertensive combinations are being used. In controlled trials, combination converting enzyme inhibitor-diuretic therapy is effective in about 85% of patients. This synergistic combination allows the diuretic dose to be reduced so that the adverse effects and metabolic complications are minimized. At this time, the combination of converting enzyme inhibitor and diuretic provides an ideal choice in terms of efficacy, compliance, side effects, and cost.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2191634

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  18 in total

Review 1.  Diuretics as a basis of antihypertensive therapy. An overview.

Authors:  N M Kaplan
Journal:  Drugs       Date:  2000       Impact factor: 9.546

2.  Slowing the progression of chronic renal insufficiency.

Authors:  Marcello Tonelli; John Gill; Sanjaya Pandeya; Clara Bohm; Adeera Levin; Bryce A Kiberd
Journal:  CMAJ       Date:  2002-04-02       Impact factor: 8.262

3.  A double-blind, placebo-controlled study to assess tolerability, pharmacokinetics and preliminary pharmacodynamics of single escalating doses of Z13752A, a novel dual inhibitor of the metalloproteases ACE and NEP, in healthy volunteers.

Authors:  M Bani; A Colantoni; M Guillaume; F Macchi; G Moroni; S Persiani
Journal:  Br J Clin Pharmacol       Date:  2000-10       Impact factor: 4.335

Review 4.  Thiazide effects and adverse effects: insights from molecular genetics.

Authors:  David H Ellison; Johannes Loffing
Journal:  Hypertension       Date:  2009-06-29       Impact factor: 10.190

Review 5.  Perindopril/indapamide 2/0.625 mg/day: a review of its place in the management of hypertension.

Authors:  A J Matheson; S M Cheer; K L Goa
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 6.  The place of diuretics in the treatment of hypertension: a historical review of classical experience over 30 years.

Authors:  A G Dupont
Journal:  Cardiovasc Drugs Ther       Date:  1993-01       Impact factor: 3.727

Review 7.  Report of the Canadian Hypertension Society Consensus Conference: 5. Hypertension and diabetes.

Authors:  K G Dawson; J K McKenzie; S A Ross; J L Chiasson; P Hamet
Journal:  CMAJ       Date:  1993-09-15       Impact factor: 8.262

Review 8.  Treatment of lupus nephritis.

Authors:  Fayez F Hejaili; Louise M Moist; William F Clark
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 9.  Pharmacokinetic drug interactions with ACE inhibitors.

Authors:  H Shionoiri
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

Review 10.  ACE inhibitors in elderly patients with hypertension. Special considerations.

Authors:  M Ravid; D Ravid
Journal:  Drugs Aging       Date:  1996-01       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.